Hospital

NS-050/NCNP-03 is being developed to aid individuals with confirmed gene mutations that are treatable with exon 50 skipping therapy.

This year the world’s first stem cell register celebrates its 50th anniversary.

Gwen Nichols, MD, discusses challenges associated with the limited access to CAR T therapy and the need to expand outpatient and community care for patients.

Mark Fendrick, MD, speaks about the importance of improving financial toxicity for patients while optimizing their outcomes.

When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.

Nick Ferreyros discusses the state and federal regulations impacting payment reform.

Breanne Peyton-Thomas, PharmD, BCOP, discusses her work as a pharmacist at Ochsner Health on the CAR T-cell therapy team.

Pharmacy students develop concept for exam augmented reality glasses for clinical situations and patient counsling.

Lalan Wilfong, MD, discusses the road to value-based care and payment reform in cancer care.

Experts debate over the most effective treatment pathway for Richter transformation, highlighting the risks and benefits of different cellular therapies.

Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies.

Alessandra Ferrajoli, MD, discusses the importance of renal function for BCL2 inhibitors to avoid tumor lysis syndrome and cardiovascular history for BTK inhibitors to mitigate arrhythmia risks.

Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.

Full traditional approval follows accelerated approval of the medication last year.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

Reid Merryman, MD, discusses the potential for minimal residual disease (MRD) to inform treatment decisions, identify lymphoma subgroups, and infer gene expression.

New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.

Pharmacy professors discuss their experience implementing a TikTok activity in their curriculum, highlighting the benefits and challenges.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.

The Center for Innovation & Value Research has released a final report recommending strategies to ensure health equity is integrated into health technology assessment, which can influence drug pricing and selection by payers, as well as patient access to drugs.

Educators describe a project where they used TikTok to encourage students to develop innovative informatics and medication safety technologies for fun, engaging learning.

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.